GEN Exclusives

More »

GEN News Highlights

More »
Oct 31, 2006

Avecia Tapped to Produce Illumigen’s Hepatitis C Drug

  • Avecia and Illumigen Biosciences entered into an agreement for the process development and manufacture of Illumigen's lead development product, IB657, for the treatment of Hepatitis C and other RNA viruses.

    Avecia will carry out development work to optimize the drug manufacturing process and conduct initial cGMP manufacture of IB657. This manufacturing agreement will provide Illumigen with IB657 in sufficient quantities to complete Phase Ia trials in Hepatitis C-infected patients.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?